Clarivate (NYSE:CLVT) Director Buys $1,209,000.00 in Stock

Posted by George Bondi on Aug 13th, 2026

Clarivate PLC (NYSE:CLVT – Get Free Report) Director Kenneth Cornick purchased 650,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was bought at an average price of $1.86 per share, for a total transaction of $1,209,000.00. Following the purchase, the director owned 1,750,000 shares in the company, valued at $3,255,000. The trade was a 59.09% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Clarivate Stock Down 2.6%

Clarivate stock opened at $1.86 on Thursday. The company’s 50-day moving average price is $2.17 and its two-hundred day moving average price is $2.34. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 0.93. The stock has a market cap of $1.19 billion, a P/E ratio of -3.58 and a beta of 1.40. Clarivate PLC has a twelve month low of $1.66 and a twelve month high of $4.55.

Clarivate (NYSE:CLVT – Get Free Report) last posted its earnings results on Wednesday, July 29th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.18 by $0.01. The company had revenue of $587.30 million for the quarter, compared to the consensus estimate of $589.73 million. Clarivate had a positive return on equity of 9.15% and a negative net margin of 13.84%.The firm’s revenue for the quarter was down 5.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.18 earnings per share. As a group, analysts expect that Clarivate PLC will post 0.67 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on CLVT. Weiss Ratings restated a “sell (e+)” rating on shares of Clarivate in a research note on Wednesday, June 24th. The Goldman Sachs Group decreased their target price on shares of Clarivate from $2.90 to $2.60 and set a “neutral” rating on the stock in a research report on Thursday, July 30th. Stifel Nicolaus lowered their target price on shares of Clarivate from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Barclays dropped their price target on shares of Clarivate from $2.50 to $2.00 and set an “underweight” rating for the company in a research report on Thursday, July 30th. Finally, Wall Street Zen downgraded Clarivate from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Clarivate presently has an average rating of “Reduce” and a consensus price target of $3.02.

Check Out Our Latest Stock Report on CLVT

Institutional Trading of Clarivate

Several institutional investors and hedge funds have recently modified their holdings of CLVT. First Trust Advisors LP raised its stake in Clarivate by 10.3% during the first quarter. First Trust Advisors LP now owns 5,522,601 shares of the company’s stock worth $13,972,000 after acquiring an additional 516,418 shares in the last quarter. KBC Group NV acquired a new stake in shares of Clarivate in the 1st quarter valued at approximately $4,118,000. Iridian Asset Management LLC CT grew its holdings in shares of Clarivate by 52.4% during the 4th quarter. Iridian Asset Management LLC CT now owns 1,528,410 shares of the company’s stock valued at $5,105,000 after purchasing an additional 525,452 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in Clarivate during the 1st quarter worth approximately $3,342,000. Finally, Empowered Funds LLC lifted its stake in Clarivate by 418.6% in the 1st quarter. Empowered Funds LLC now owns 2,015,829 shares of the company’s stock valued at $5,100,000 after purchasing an additional 1,627,159 shares during the last quarter. 85.72% of the stock is currently owned by institutional investors.

Clarivate Company Profile

(Get Free Report)

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.